Amicus Therapeutics, Inc.
Amicus and GSK Expanded Fabry Collaboration Call
July 17, 2012 05:00 pm ET
John Crowley – Chairman & Chief Executive Officer
David Lockhart – Chief Scientific Officer
Pol Boudes, MD – Chief Medical Officer
Chip Baird – Chief Financial Officer
Bradley Campbell – Chief Business Officer
Sara Pellegrino – Associate Director, Investor Relations
Ritu Baral – Canaccord Genuity
Anupam Rama – JP Morgan
Kim Lee – ThinkEquity
Bill Tanner – Lazard Capital Markets
Good day, ladies and gentlemen, and welcome to your Amicus and GSK Expanded Fabry Collaboration Call. (Operator instructions.) As a reminder, today’s conference is being recorded. And now I would like to introduce your host for today, Sara Pellegrino.
Good afternoon and thank you for joining our conference call to discuss the expansion of our collaboration with GSK to develop and commercialize co-formulations of migalastat for Fabry disease. Speaking on today’s call we have John Crowley, our Chairman and Chief Executive Officer; Bradley Campbell, our Chief Business Officer; and David Lockhart, our Chief Scientific Officer. They are joined by Chip Baird, our Chief Financial Officer, and Pol Boudes, our Chief Medical Officer, who are available to participate in the Q&A Session.
As a reminder, the presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business, operations and financial conditions of Amicus including but not limited to preclinical and clinical development of Amicus candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus’ candidate drug products, the projected cash position for the company and business development and other transactional activities. Words such as but not limited to “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “would,” “should,” and “could,” and similar expressions and words identify forward-looking statements.